JP2017514805A - Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 - Google Patents

Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 Download PDF

Info

Publication number
JP2017514805A
JP2017514805A JP2016562761A JP2016562761A JP2017514805A JP 2017514805 A JP2017514805 A JP 2017514805A JP 2016562761 A JP2016562761 A JP 2016562761A JP 2016562761 A JP2016562761 A JP 2016562761A JP 2017514805 A JP2017514805 A JP 2017514805A
Authority
JP
Japan
Prior art keywords
cancer
tor kinase
substituted
kinase inhibitor
dihydropyrazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514805A5 (enExample
Inventor
トロウェ トルステン
トロウェ トルステン
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2017514805A publication Critical patent/JP2017514805A/ja
Publication of JP2017514805A5 publication Critical patent/JP2017514805A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016562761A 2014-04-16 2015-04-15 Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 Pending JP2017514805A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980125P 2014-04-16 2014-04-16
US61/980,125 2014-04-16
PCT/US2015/025844 WO2015160869A1 (en) 2014-04-16 2015-04-15 Methods for treating cancer using tor kinase inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2017514805A true JP2017514805A (ja) 2017-06-08
JP2017514805A5 JP2017514805A5 (enExample) 2018-05-17

Family

ID=54321050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562761A Pending JP2017514805A (ja) 2014-04-16 2015-04-15 Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法

Country Status (5)

Country Link
US (1) US20150297605A1 (enExample)
EP (1) EP3131550B1 (enExample)
JP (1) JP2017514805A (enExample)
ES (1) ES2881863T3 (enExample)
WO (1) WO2015160869A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506875A (ja) * 2008-10-27 2012-03-22 シグナル ファーマシューティカルズ，エルエルシー ｍＴＯＲ／ＰＩ３Ｋ／ＡＫＴ経路と関連した腫瘍学的徴候及び疾患のためのｍＴＯＲキナーゼ阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004184A2 (en) * 2006-04-05 2008-12-24 Novartis AG Combinations of therapeutic agents for treating cancer
EP2361248B1 (en) * 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2013050596A1 (en) 2011-10-06 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of maintaining foxp3 expression in expanded t regulatory cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506875A (ja) * 2008-10-27 2012-03-22 シグナル ファーマシューティカルズ，エルエルシー ｍＴＯＲ／ＰＩ３Ｋ／ＡＫＴ経路と関連した腫瘍学的徴候及び疾患のためのｍＴＯＲキナーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLIN. EPIGENET., vol. 1, JPN6019002915, 2010, pages 25 - 44, ISSN: 0004107455 *

Also Published As

Publication number Publication date
WO2015160869A1 (en) 2015-10-22
EP3131550A1 (en) 2017-02-22
EP3131550B1 (en) 2021-05-26
NZ629859A (en) 2015-12-24
ES2881863T3 (es) 2021-11-30
US20150297605A1 (en) 2015-10-22
EP3131550A4 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
JP6838085B2 (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
ES2894958T3 (es) Tratamiento del cáncer con inhibidores de la quinasa TOR
US10391092B2 (en) Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
KR102271344B1 (ko) 디하이드로피라지노-피라진을 사용한 암의 치료
JP6382948B2 (ja) 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
JP2018065820A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2015510891A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2016516818A (ja) 癌を治療するためのｔｏｒキナーゼ阻害剤及びｎ−（３−（５−フルオロ−２−（４−（２−メトキシエトキシ）フェニルアミノ）ピリミジン−４−イルアミノ）フェニル）アクリルアミドを含む組合せ療法
JP2015511963A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2016522177A (ja) ジヒドロピラジノ−ピラジンによる癌治療
JP2016516671A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの治療
JP2017514805A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190903